|
1) 槇村浩一. 我が国における病原真菌と健康障害ならびに対策の現状. 日本細菌学会雑誌. 2007; 62: 295-312
|
|
|
|
|
2) 久米 光, 山崎敏和, 阿部美知子, 他. 白血病(MDSを含む)剖検例における内臓真菌症の疫学 ─日本病理剖検輯報(1990, 1994, 1998, 2002年版)の解析─. 真菌誌. 2006; 47: 15-24
|
|
|
|
|
3) Takakura S, Fujihara N, Saito T, et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004; 53: 283-9
|
|
|
|
|
|
4) 山口英世, 内田勝久, 奥住捷子, 他. Japan antifungal surveillance programによる真菌臨床分離株の抗真菌感受性に関する調査(1): 2001～2002年度報告. 日本臨床微生物学会雑誌. 2004; 14: 183-93
|
|
|
|
|
|
5) 山口英世, 内田勝久, 西山彌生, 他. Japan antifungal surveillance programによる真菌臨床分離株の抗真菌感受性に関する調査研究(2): 2003年度報告. 日本臨床微生物学会雑誌. 2006; 16: 13-22
|
|
|
|
|
|
6) Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses. 2005; 48: 246-50
|
|
|
|
|
|
7) Dannaoui E, Meletiadis J, Mouton JW, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003; 51: 45-52
|
|
|
|
|
|
8) Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002; 46: 1032-7
|
|
|
|
|
|
9) Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003; 41: 78-83
|
|
|
|
|
|
10) Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003; 41: 3623-6
|
|
|
|
|
|
11) Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, et al. Comparative in-vitro activity of voriconazole (UK-109, 496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 1999; 43: 149-51
|
|
|
|
|
|
12) Yustes C, Guarro J. In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother. 2005; 49: 3498-500
|
|
|
|
|
|
13) Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003; 20: 121-36
|
|
|
|
|
|
14) Kohler LM, Monteiro PC, Hahn RC, et al. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J Clin Microbiol. 2004; 42: 4319-20
|
|
|
|
|
|
15) 槙村浩一. 耐性菌の基礎と臨床 主として院内感染で問題となる耐性菌 真菌(基礎編). 臨床検査. 2006; 50: 813-7
|
|
|
|
|
16) Nakai T, Uno J, Ikeda F, et al. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother. 2003; 47: 1376-81
|
|
|
|
|
|
17) Walsh TJ, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999; 340: 764-71
|
|
|
|
|
|
18) National Committee for Clinical Laboratory Standards (NCCLS): Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-second edition. document M27-A2 Vol. 22 No. 15. National Committee for Clinical Laboratory Standards, Wayne: Pa; 2002
|
|
|
|
|
|
19) 相川直樹. 真菌症治療薬の新しい展開 ホスフルコナゾール(フルコナゾールプロドラッグ). 化学療法の領域(0913-2384). 2003; 19: 211-4
|
|
|
|
|
|
20) Herbrecht R, Denning DW, Patterson TF, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408-15
|
|
|
|
|